Cardiotoxicity: all 269 studies
Page 3 of 3. Open to participants first (71), then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related CardiotoxicityTerminatedNCT03089502Not applicable
- Early Detection of Cardiac Toxicity in Childhood Cancer SurvivorsTerminatedNCT03038997
- The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.Active, not recruitingNCT02942615Not applicable
- Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-CellCompletedNCT02916316
- Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in TanzaniaCompletedNCT02909712Phase 2
- Assessment of Global Longitudinal Strain for the Prediction of Anthracycline Induced CardiotoxicityCompletedNCT02875171
- Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related CardiotoxicityCompletedNCT02798679
- Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via ChemotherapyCompletedNCT02796365Not applicable
- Cardiotoxicity of Radiation Therapy (CTRT)CompletedNCT02769299
- Imaging Markers of Subclinical Cardiotoxicity in Breast CancerCompletedNCT02666378
- Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving FluoropyrimidineStatus unknownNCT02665312
- Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional EndotheliumCompletedNCT02652975Not applicable
- Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer SurvivorsCompletedNCT02615054
- BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT StudyCompletedNCT02605512Not applicable
- The Cardio-Oncology Breast Cancer StudyStatus unknownNCT02571894Not applicable
- Effect of Remote Ischaemic Conditioning in Oncology PatientsStatus unknownNCT02471885Not applicable
- Exercise to Prevent AnthrCycline-based Cardio-Toxicity StudyCompletedNCT02471053Not applicable
- Cardiac Toxicity in Medical Treatment of Breast CancerCompletedNCT02440620
- Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing DoxorubicinCompletedNCT02423356
- Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRIActive, not recruitingNCT02306538
- Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced CardiotoxicityCompletedNCT02274480
- Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or TrastuzumabStatus unknownNCT02236806Phase 3
- PhysioFlow to Detect Cardiotoxicity in ChemoStatus unknownNCT02220569
- Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian VolunteersStatus unknownNCT02119091Phase 1
- Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and TaxanesStatus unknownNCT02101879
- Early Detection of Broken Hearts in Cancer PatientsCompletedNCT02086695
- REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity)WithdrawnNCT02079272Not applicable
- Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast CancerCompletedNCT02065908
- Early Predictor of Herceptin Cardio Toxicity in Breast Cancer PatientsSuspendedNCT02062983
- Spironolactone Against Anthracycline-induced CardiomyopathyCompletedNCT02053974Phase 4
- Prevention of Anthracycline-induced CardiotoxicityActive, not recruitingNCT01968200Phase 3
- Preventing Cardiac Sequelae in Pediatric Cancer SurvivorsCompletedNCT01805778
- Carvedilol Effect in Preventing Chemotherapy - Induced CardiotoxicityCompletedNCT01724450Phase 3
- Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced CardiotoxicityCompletedNCT01665300
- Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast CancerCompletedNCT01572883
- Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance ImagingTerminatedNCT01436604Phase 2
- Sunitinib and Atrial Trabeculae ContractilityCompletedNCT01246778
- Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's LymphomaCompletedNCT01230983Phase 3
- Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D StrainCompletedNCT01212926Not applicable
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast CancerStatus unknownNCT01093235Phase 3
- Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)Status unknownNCT01032278Not applicable
- Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving TrastuzumabStatus unknownNCT01022086
- Evaluation of Radiation Induced Toxicity to the Heart by Multi-detector Computed Tomography (MDCT)Status unknownNCT01018719
- A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)CompletedNCT01014065
- CADY Study ICORG 08-01CompletedNCT00968682
- Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and TrastuzumabCompletedNCT00875238
- Cardiotoxicity of Adjuvant TrastuzumabCompletedNCT00858039
- Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCLCompletedNCT00854568Phase 3
- Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer PatientsCompletedNCT00806507
- Aerobic Exercise in Patients Receiving Chemotherapy for CancerTerminatedNCT00728429Not applicable
- Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)TerminatedNCT00679874
- Detection of Chemotherapy Induced CardiotoxicityCompletedNCT00636844
- Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell LymphomaCompletedNCT00575406Phase 2
- Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation TherapyTerminatedNCT00563407
- Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib ChemotherapyTerminatedNCT00532064
- The Magnetic Resonance Imaging Evaluation of Doxorubicin CardiotoxicityCompletedNCT00530101Phase 1
- Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated CardiotoxicityCompletedNCT00459771Phase 3
- Prevention of Chemotherapy-induced Cardiotoxicity in High-risk PatientsCompletedNCT00292526Phase 4
- Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline ChemotherapyTerminatedNCT00247975Phase 2/3
- Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)TerminatedNCT00195897
- Prevention of CHOP-induced Chronic CardiotoxicityCompletedNCT00162955Phase 4
- Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid TumorsCompletedNCT00039481Phase 1
- Combination Chemotherapy Before and After Surgery in Treating Patients With OsteosarcomaTerminatedNCT00019864Phase 2
- Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast CancerTerminatedNCT00016276Phase 3
- Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's DiseaseCompletedNCT00005578Phase 3
- Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic OsteosarcomaCompletedNCT00003937Phase 3
- Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood CancerCompletedNCT00003070Phase 3
- SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical TrialCompletedNCT00002900
- Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's DiseaseCompletedNCT00002827Phase 3